CORDANI, NICOLETTA

CORDANI, NICOLETTA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 36 (tempo di esecuzione: 0.029 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Angiogenesis-Related New Mechanisms for Chemotherapy-Induced Painful Peripheral Neuropathy in the Rat 02 - Intervento a convegno 2024 Valentina Alda CarozziVirginia Rodriguez-MenendezEleonora PozziAnnalisa CantaAlessia ChiorazziElisa BallariniPaola AlbertiCristina MeregalliNicoletta CordaniDaniele RamazzottiAlberto BravinGuido Cavaletti +
CENTRAL AND PERIPHERAL MICROVASCULAR NETWORK IS ABNORMAL IN RATS WITH PAINFUL-CHEMOTHERAPY INDUCED NEUROPATHY: NEW PATHOPHYSIOLOGICAL MECHANISMS OVER THE HORIZON? 02 - Intervento a convegno 2024 Carozzi VAPozzi ECanta AChiorazzi ACordani NAlberti PMeregalli CCavaletti G +
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Edaravone: A Novel Possible Drug for Cancer Treatment? 01 - Articolo su rivista 2024 Duranti E.Cordani N.Villa C.
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 01 - Articolo su rivista 2024 Villa, MatteoMalighetti, FedericaSharma, Geeta G.Manfroni, ChiaraFontana, DilettaCordani, NicolettaMeneveri, RaffaellaPiazza, RoccoPagni, FabioCortinovis, DiegoMologni, Luca +
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 01 - Articolo su rivista 2023 Cordani N.Bianchi T.Cortinovis D. L.Cazzaniga M. E.Lissoni A. A.Landoni F. +
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 02 - Intervento a convegno 2023 Gotuzzo, ICazzaniga, MDe Bernardi, ECicchiello, FCordani, NCerrito, MTurolla, ELandoni, CCrivellaro, CVirdone, LMonaco, LGuerra, L +
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 01 - Articolo su rivista 2023 Nicoletta CordaniGiuseppe PagliaRamona MeantiMaria Grazia CerritoChiara VillaMario MauriLuca MologniAntonio TorselloMarina Elena Cazzaniga +
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 02 - Intervento a convegno 2023 Nicoletta CordaniLuca MologniRocco PiazzaCamillo Di BellaMaria Grazia CerritoMatteo VillaGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 01 - Articolo su rivista 2023 Nicoletta CordaniLuca MologniRocco PiazzaPietro TettamantiMario MauriMatteo VillaFederica MalighettiCamillo Di BellaMaria Grazia CerritoGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 01 - Articolo su rivista 2022 Scagliotti A.Capizzi L.Cazzaniga M. E.Ilari A.Cordani N.Albini A.Lavitrano M.Grassilli E.Cerrito M. G. +
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 01 - Articolo su rivista 2022 Cortinovis D. L.Abbate M. I.Cordani N. +
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 01 - Articolo su rivista 2022 Cicchiello F.Cordani N.Cerrito M. G.Cazzaniga M. E. +
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 01 - Articolo su rivista 2022 Cazzaniga M. E.Baroni S.Cicchiello F.Cordani N.Cerrito M. G. +
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 01 - Articolo su rivista 2022 Marina Elena CazzanigaNicoletta CordaniMaria Grazia Cerrito +
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 02 - Intervento a convegno 2022 Villa, MMalighetti, FArosio, GManfroni, CFontana, DCordani, NMeneveri, RZambon, APiazza, RPagni, FCortinovis, DMologni, L +
Metronomic chemotherapy 01 - Articolo su rivista 2021 Cazzaniga M. E.Cordani N.Cerrito M. G. +
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 01 - Articolo su rivista 2019 Sharma G. G.Cortinovis D.Villa M.Cordani N.Bidoli P.Pagni F.Piazza R.Gambacorti-Passerini C.Mologni L. +
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 01 - Articolo su rivista 2018 Redaelli, SaraCeccon, MonicaSharma, Geeta GMastini, CristinaMauri, MarioMassimino, LucaCordani, NicolettaFarina, FrancescaPiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 99 - Altro 2017 Piazza, RRamazzotti, DSpinelli, RPirola, AMagistroni, VCordani, NGambacorti-Passerini, C +